Stock Analysis on Net
Stock Analysis on Net

DexCom Inc. (NASDAQ:DXCM)

This company has been moved to the archive! The financial data has not been updated since October 26, 2023.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

DexCom Inc., EBITDA calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income (loss) 341,200 154,700 493,600 101,100 (127,100)
Add: Income tax expense 49,600 19,200 (268,600) 3,100 600
Earnings before tax (EBT) 390,800 173,900 225,000 104,200 (126,500)
Add: Interest expense 18,600 100,300 84,700 60,300 22,700
Earnings before interest and tax (EBIT) 409,400 274,200 309,700 164,500 (103,800)
Add: Depreciation and amortization 155,900 102,000 67,100 48,700 29,100
Earnings before interest, tax, depreciation and amortization (EBITDA) 565,300 376,200 376,800 213,200 (74,700)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial performance between 2018 and 2022 is characterized by a significant transition from operational losses to sustained profitability. A consistent upward trajectory is observed across all key earnings metrics, with the most substantial recovery occurring between 2018 and 2019.

EBITDA Trend Analysis
Earnings before interest, tax, depreciation and amortization experienced a sharp reversal from a loss of US$ 74.7 million in 2018 to a positive US$ 213.2 million in 2019. Growth continued through 2020, reaching US$ 376.8 million, before stabilizing in 2021 at US$ 376.2 million. A final surge occurred in 2022, with EBITDA peaking at US$ 565.3 million, representing a substantial increase in cash-flow generative capacity over the five-year period.
Comparative Profitability Metrics
A divergence is noted between EBITDA and Net Income, particularly in 2020 and 2021. While EBITDA remained nearly flat between 2020 and 2021, Net Income decreased sharply from US$ 493.6 million to US$ 154.7 million. This suggests that while core operational cash flow remained stable, other factors—such as taxes, interest, or non-recurring items—materially impacted the final bottom line during that period.
Operating Expenses and Depreciation
The widening gap between EBIT and EBITDA indicates an increase in depreciation and amortization expenses over time. In 2018, the difference was approximately US$ 28.9 million, which expanded to US$ 155.9 million by 2022. This trend is indicative of increased capital investment in assets to support scaling operations.
Overall Earnings Trajectory
Earnings before tax (EBT) and Earnings before interest and tax (EBIT) mirrored the general upward trend of EBITDA, though with more volatility. EBIT grew from a loss of US$ 103.8 million in 2018 to US$ 409.4 million in 2022, confirming that the improvement in profitability is driven by core operating performance rather than financial engineering or one-time gains.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Enterprise Value to EBITDA Ratio, Current

DexCom Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV) 30,908,961
Earnings before interest, tax, depreciation and amortization (EBITDA) 565,300
Valuation Ratio
EV/EBITDA 54.68
Benchmarks
EV/EBITDA, Competitors1
Abbott Laboratories 14.36
Elevance Health Inc. 8.27
Intuitive Surgical Inc. 33.26
Medtronic PLC 13.24
UnitedHealth Group Inc. 16.92
EV/EBITDA, Sector
Health Care Equipment & Services 13.39
EV/EBITDA, Industry
Health Care 18.66

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

DexCom Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1 41,016,904 38,537,513 38,474,254 22,641,443 12,793,858
Earnings before interest, tax, depreciation and amortization (EBITDA)2 565,300 376,200 376,800 213,200 (74,700)
Valuation Ratio
EV/EBITDA3 72.56 102.44 102.11 106.20 —
Benchmarks
EV/EBITDA, Competitors4
Abbott Laboratories 15.85 17.42 — — —
Elevance Health Inc. 10.26 10.05 — — —
Intuitive Surgical Inc. 40.96 44.10 — — —
Medtronic PLC 14.99 24.41 — — —
UnitedHealth Group Inc. 15.11 17.39 — — —
EV/EBITDA, Sector
Health Care Equipment & Services 15.26 18.05 — — —
EV/EBITDA, Industry
Health Care 14.00 14.33 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 41,016,904 ÷ 565,300 = 72.56

4 Click competitor name to see calculations.


The financial trajectory from 2018 to 2022 is characterized by a substantial expansion in enterprise value and a transition from operational losses to consistent profitability.

Enterprise Value Trends
A significant upward trend in enterprise value is observed, increasing from 12.79 billion US$ in 2018 to 41.02 billion US$ in 2022. The most rapid growth occurred between 2018 and 2020, where the value nearly tripled, followed by a period of relative stabilization and moderate growth through 2021 and 2022.
EBITDA Evolution
Operational performance shifted from a negative EBITDA of 74.7 million US$ in 2018 to a positive 565.3 million US$ by 2022. Following the achievement of profitability in 2019, earnings grew steadily, with a notable acceleration in growth recorded between 2021 and 2022.
EV/EBITDA Ratio Analysis
The EV/EBITDA ratio remained exceptionally high between 2019 and 2021, fluctuating between 102.11 and 106.20, indicating a market valuation based on high growth expectations. A notable contraction in this multiple occurred in 2022, falling to 72.56. This reduction is driven by the fact that EBITDA growth in the final period significantly outpaced the increase in enterprise value, leading to a relative compression of the valuation multiple.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?